Company Profile

Sorrento Therapeutics Inc (AKA: STI)
Profile last edited on: 4/2/22      CAGE: 5SPZ9      UEI: KWEWLHZ59FL3

Business Identifier: Immuno-oncology and pain management
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4955 Directors Place
San Diego, CA 92121
Location: Single
Congr. District: 52
County: San Diego

Public Profile

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is a publicly-traded, clinical-stage biopharmaceutical company structured around acquisition, discovery, development and commercialization of proprietary oncology therapeutics. The company's primary focus is oncology, including treatment of chronic cancer pain, as well as developing therapeutic products for other indications, such as immunology and infectious diseases. The company offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. Sorrento is also developing CD38 Directed chimeric antigen receptor T-cell therapy (CAR-T) for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases; carcinoembryonic antigen CAR-T cell therapy for the treatment of liver metastases of pancreatic cancer; and various human antibodies. The firmalso has a cooperation framework agreement with LifeTech Scientific Corporation for the research and development, production, and commercialization of water-soluble cannabidiol and other water-soluble cannabinoids products

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2015 2 NIH $586,535
Project Title: Anti-Pseudomonas Immunotherapy and Targeted Drug Delivery
2015 2 NIH $2,595,459
Project Title: Human Monoclonal Antibodies for Prevention of S. Aureus Infections
2014 1 NIH $224,550
Project Title: Targeting of Myc-Max Dimerization for the Treatment of Cancer
2014 1 NIH $224,823
Project Title: Human Anti-Wisp1 Antibodies for Treatment of Idiopathic Pulmonary Fbrosis
2012 2 NIH $592,716
Project Title: A Vaccine Against Clostridium Difficile Infections

Key People / Management

  Henry Ji -- Founder, Interim CEO & Chief Scientific Officer

  Gunnar Joerg Floris Kaufmann

  Charles P Rodi

  Barbara A Swanson

  Vuong Trieu -- CSO

  Richard G Vincent -- Chief Financial Officer